Search research articles
Contact Us
Filters
Showing results (211-220 of 224) with videos related to
Page
of 23
Sort By:
La Revue De Medecine Interne
|
January 1, 1997
[Limitations of the protein profile for diagnostic orientation in initial internal medicine consultation. Prospective study on 76 patients]
J H Barrier, M Herbouiller, D Le Carrer, et al.
Medecine Et Maladies Infectieuses
|
December 26, 2018
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study)
C Allavena, C Volteau, E André-Garnier, et al.
Antiviral Therapy
|
January 6, 2001
The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults
F Raffi, V Reliquet, V Ferré, et al.
Journal of Viral Hepatitis
|
July 8, 2000
Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients
L Piroth, M Grappin, L Cuzin, et al.
HIV Medicine
|
November 28, 2015
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy
A Winston, W Stöhr, A Antinori, et al.
HIV Medicine
|
December 12, 2001
MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine
C Katlama, J L Pellegrin, D Lacoste, et al.
JAMA
|
March 20, 2001
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
S Staszewski, P Keiser, J Montaner, et al.
The Journal of Infection
|
July 10, 2003
Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study
F Roblot, G Le Moal, C Godet, et al.
HIV Medicine
|
September 19, 2019
Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial
B Alejos, N Stella-Ascariz, R Montejano, et al.
The Journal of Antimicrobial Chemotherapy
|
December 26, 2015
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
S Lambert-Niclot, E C George, A Pozniak, et al.
Page
of 23
Search research articles
Search
Showing results (211-220 of 224) with videos related to
Sort By:
Page
of 23
La Revue De Medecine Interne
|
January 1, 1997
[Limitations of the protein profile for diagnostic orientation in initial internal medicine consultation. Prospective study on 76 patients]
J H Barrier, M Herbouiller, D Le Carrer, et al.
Medecine Et Maladies Infectieuses
|
December 26, 2018
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study)
C Allavena, C Volteau, E André-Garnier, et al.
Antiviral Therapy
|
January 6, 2001
The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults
F Raffi, V Reliquet, V Ferré, et al.
Journal of Viral Hepatitis
|
July 8, 2000
Hepatitis C virus co-infection is a negative prognostic factor for clinical evolution in human immunodeficiency virus-positive patients
L Piroth, M Grappin, L Cuzin, et al.
HIV Medicine
|
November 28, 2015
Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy
A Winston, W Stöhr, A Antinori, et al.
HIV Medicine
|
December 12, 2001
MIKADO: a multicentre, open-label pilot study to evaluate the antiretroviral activity and safety of saquinavir with stavudine and zalcitabine
C Katlama, J L Pellegrin, D Lacoste, et al.
JAMA
|
March 20, 2001
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial
S Staszewski, P Keiser, J Montaner, et al.
The Journal of Infection
|
July 10, 2003
Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study
F Roblot, G Le Moal, C Godet, et al.
HIV Medicine
|
September 19, 2019
Determinants of blood telomere length in antiretroviral treatment-naïve HIV-positive participants enrolled in the NEAT 001/ANRS 143 clinical trial
B Alejos, N Stella-Ascariz, R Montejano, et al.
The Journal of Antimicrobial Chemotherapy
|
December 26, 2015
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART
S Lambert-Niclot, E C George, A Pozniak, et al.
Page
of 23